NEWTON TRIAL - Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage

Trial Profile

NEWTON TRIAL - Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Feb 2017

At a glance

  • Drugs Nimodipine (Primary) ; Nimodipine
  • Indications Cerebral ischaemia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms NEWTON
  • Sponsors Edge Therapeutics
  • Most Recent Events

    • 24 Feb 2017 Results presented at the 42nd International Stroke Conference
    • 09 Dec 2016 According to an Edge Therapeutics media release, results of this trial are scheduled for print publication in the January 2017 issue of Stroke.
    • 09 Dec 2016 Results published in the an Edge Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top